Alliancebernstein L.P. Chimerix Inc Transaction History

Alliancebernstein L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.67 - $2.35 $18,704 - $26,320	11,200 Added 7.79%	154,900 $288,000
Q3 2022 Nov 15, 2022	BUY	$1.81 - $2.76 $62,988 - $96,047	34,800 Added 31.96%	143,700 $277,000
Q2 2022 Aug 15, 2022	BUY	$1.34 - $5.34 $46,364 - $184,764	34,600 Added 46.57%	108,900 $227,000
Q1 2022 May 13, 2022	BUY	$4.58 - $6.8 $1,374 - $2,040	300 Added 0.41%	74,300 $340,000
Q1 2021 May 06, 2021	SELL	$4.76 - $11.25 $133,280 - $315,000	-28,000 Reduced 27.45%	74,000 $713,000
Q2 2020 Aug 13, 2020	BUY	$1.33 - $3.63 $38,570 - $105,270	29,000 Added 39.73%	102,000 $316,000
Q1 2020 May 14, 2020	BUY	$1.27 - $2.33 $7,112 - $13,048	5,600 Added 8.31%	73,000 $105,000
Q2 2019 Aug 14, 2019	BUY	$2.05 - $4.32 $7,174 - $15,120	3,500 Added 5.48%	67,400 $291,000
Q1 2019 May 14, 2019	SELL	$1.79 - $3.12 $11,098 - $19,344	-6,200 Reduced 8.84%	63,900 $134,000
Q2 2018 Aug 13, 2018	BUY	$4.43 - $5.14 $14,176 - $16,448	3,200 Added 4.78%	70,100 $334,000
Q4 2017 Feb 13, 2018	SELL	$4.32 - $5.52 $4,320 - $5,520	-1,000 Reduced 1.47%	66,900 $310,000
Q3 2017 Nov 13, 2017	BUY	$4.35 - $5.25 $295,365 - $356,475	67,900	67,900 $356,000

36.8M

72.2K

169K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.